PC
EIDX

Polar Capital’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Polar Capital’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-110,094
Closed -$3.42M – 314
2019
Q2 		$3.42M Buy
+110,094
New +$2.98M 0.03% 242

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Polar Capital's EIDX Position: Q3 2019 in Review

Polar Capital sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q3 2019, closing a stake of 110,094 shares — an estimated $3.42M sold.

Polar Capital first reported a position in EIDX in Q2 2019 and held it in 1 quarter. The position peaked at $3.42M in Q2 2019. 79 funds tracked by Wall St. Rank hold EIDX as of Q3 2019.

  • Polar Capital reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Polar Capital sold 110,094 Eidos Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $3.42M.
  • Polar Capital first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Polar Capital's Eidos Therapeutics, Inc. Common Stock position peaked at $3.42M in Q2 2019.
  • 79 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Polar Capital's 13F filing for Q3 2019, filed 14 Nov 2019.